Skip to content

Omnipod 5 ACE Pump

by Insulet Corporation

510(k) K231826

Omnipod 5 ACE Pump is a medical device (FDA Class II; FDA product code QFG, Alternate Controller Enabled Insulin Infusion Pump) made by Insulet Corporation, cleared under FDA 510(k) K231826 on 18 Oct 2023, active as of 22 Oct 2026. 3 FDA recalls are linked to it.

Active United States

510(k)

Valid until

No expiry

510(k) clearance is not time-limited

FDA recalls

5 ongoing

This device is named in the recall

Documents

Trust

Unverified

Source FDA 510(k), synced 22 Oct 2026.

Regulatory status

as of registry sync 22 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA 510(k)SESE Substantially Equivalent · Traditional NumberK231826 Date18 Oct 2023ClearedStatusActive

Official records

From the FDA record

Received by the FDA
21 Jun 2023
FDA decision
18 Oct 2023 (Substantially Equivalent)
FDA review time
119 days from receipt to decision
Public document
510(k) summary on file with the FDA

From the FDA 510(k) record K231826 (openFDA), as read on 22 Oct 2026. Quoted as published, gaps included; nothing on this list is generated.

Recalls

5 recalls · 5 ongoing · FDA

    • Ongoing Z-2603-2026 FDA Class I initiated 20 May 2026

    External soft cannula damage during manufacturing that results in insulin leaking around the Pod instead of being delivered to the user regardless of basal or bolus delivery. The primary failure mode is pump under-delivery due to loss of insulin to an external leak. If insulin is not delivered properly, users may experience high blood glucose levels due to under-delivery of insulin. In the most severe cases, prolonged and persistent high blood glucose levels can lead to diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar syndrome (HHS), or even death.

    • Ongoing Z-1797-2026 FDA Class I initiated 12 Mar 2026

    Due to a manufacturing defect, certain Omnipod 5 Pods from 49 lots have an internal soft cannula tear that results in insulin leaking into the Pod instead of being delivered to the user regardless of basal or bolus delivery. This defect results from damage to the unexposed portion of the soft cannula during manufacturing, which would result in a compromised fluid path. The primary failure mode is pump under-delivery due to loss of insulin to an internal leak; in some cases, the defect may also lead to pump shutoff and cessation of insulin delivery when leaked insulin contacts Pod circuity in a manner that results in an electrical short. Under-delivery of insulin (both basal and bolus insulin) or cessation of insulin put users at risk of hyperglycemia, and complications from acute and chronic hyperglycemia, including dehydration, blurry vision, nausea, vomiting, altered mental status, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar syndrome (HHS), or even death. Users may require hospitalization or medical intervention to treat severe adverse health consequences. Not all devices with the defect will issue an alarm or alert the user. If there is sufficient leakage of insulin to cause a short in the circuity, the Pod will issue a Hazard Alarm that stops all insulin delivery and alerts the user to replace their Pod. In addition, if a user s glucose is trending high and is not responding to insulin delivery, the system may reach the maximum amount of insulin microboluses allowed by the system and trigger the Automated Delivery Restriction (ADR) alert that tells users to check their blood glucose and take appropriate actions (i.e., ADR is a response to persistent hyperglycemia and maximum automated delivery constraints rather than a direct detection of the leak). The magnitude of under-delivery is unknown and based on multiple factors, including how much insulin is being delivered, whether an alarm and/or alert triggers, whether and when the user recognizes the device defect, the duration of Pod use, and the size of the tear.

    • Ongoing Z-0132-2026 FDA Class II initiated 11 Sep 2025 on shared 510(k) K231826

    The failure occurs if a user on the Omnipod 5 iOS application selects and holds down on a manual entry field, to magnify the visual field using the magnifying feature of the iPhone, while simultaneously selecting a single number on the keyboard. This causes the single digit number to duplicate. This could result in errors in manual entry of digits - examples: bolus entry, I:C ratio, bolus calculator, prior to starting the bolus insulin delivery. Therefore, this may result in over delivery of insulin which may cause hypoglycemia.

    • Ongoing Z-2016-2025 FDA Class II initiated 23 May 2025 on shared 510(k) K231826

    Insulet Corporation is recalling Omnipod 5 iOS App, due to a software design issue in which a comma is not recognized as a decimal separator and the user cannot enter a decimal separator in any manual entry screen if the user manually updates their phone settings to a region OUS that uses a decimal separator instead of a period decimal separator or chooses that format as a preference. Use of the affected software may result in over delivery of insulin by increasing the amount of insulin when a decimal separator is not recognized (e.g., 0.1 unit recognized as 1 unit) and thus may result in hypoglycemia, potentially severe.

    • Ongoing Z-0591-2024 FDA Class I initiated 30 Nov 2023

    The bolus calculator is not recording the decimal point if it is the first value entered when changing a bolus dose. This may lead to an over-delivery of insulin to the user if the user does not recognize the error on the bolus calculator screen or the confirmation screen prior to starting the bolus.

Recalls on a shared submission name another device cleared under the same FDA submission as this one.

Timeline

6 dated events

  1. Cleared FDA 510(k) K231826
  2. Recall initiated FDA recalls Z-0591-2024
  3. Recall initiated FDA recalls Z-2016-2025
  4. Recall initiated FDA recalls Z-0132-2026
  5. Recall initiated FDA recalls Z-1797-2026
  6. Recall initiated FDA recalls Z-2603-2026

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Specification

510(k)

510(k) Number
FDA product code
QFG
Device class
Class II
Regulation
21 CFR Part 880.5730
Advisory committee
Clinical Chemistry
FDA decision
SESE Substantially Equivalent

Similar devices

Other devices filed under FDA product code QFG (Alternate Controller Enabled Insulin Infusion Pump).

Other devices from Insulet Corporation

See all devices from Insulet Corporation →